{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:51:31Z","timestamp":1790715091474,"version":"4.1.0"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Suppl 2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Lung cancer is one of the major causes of morbidity and mortality both in developed and developing countries. Adverse drug reactions (ADRs) are inevitable, albeit unwanted aspects of cancer chemotherapeutic agents used in lung cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim and Objectives:<\/jats:title>\n                    <jats:p>To determine common ADRs and the severity of ADRs of different chemotherapeutic agents used in non-small cell lung cancer (NSCLC) patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>The study was conducted among purposively selected 160 patients who had undergone chemotherapy for lung carcinoma. Clinical records of NSCLC patients were reviewed and data related to the socio-demographic and clinic-therapeutic profiles of patients were collected. ADRs were graded according to the Common toxicity criteria (CTC) grading. Data analysis was done using the IBM-SPSS software and presented using the principle of descriptive statistics. Relationships between ADRs and drug regimens were determined using Chi-square tests considering a 95% confidence interval and P value \u2264 0.05 as significant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Result:<\/jats:title>\n                    <jats:p>Among 160 patients, 78.8% were males and 21.3% were females. The mean age was 59.15 \u00b1 10.6 years, illness duration was 7.5 \u00b1 10.6 months, and treatment duration was 4.4 \u00b1 0.91 months. The overall mortality rate and systemic toxicity of the paclitaxel\u2013carboplatin combination were the lowest. Almost an equal proportion of moderate to severe changes in parameters such as myelosuppression, anemia, thrombocytopenia, alopecia, skin changes, allergic reaction, and peripheral neuropathy, were observed with all chemotherapeutic regimens. Gemcitabine\u2013carboplatin regimen was associated with a higher proportion of altered liver enzymes, electrolyte imbalance, diarrhea, pleural effusion, and renal toxicities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>There was a high prevalence of ADRs with different chemotherapeutic agents. Early detection of these ADRs may help in minimizing the damage by either modifying the dose or changing the offending agent.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_522_22","type":"journal-article","created":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T03:01:09Z","timestamp":1708484469000},"page":"S786-S791","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Evaluation of adverse drug reactions of chemotherapeutic agents used in advanced non-small cell lung cancer \u2013 experience from a rural tertiary care institution in North Eastern India"],"prefix":"10.4103","volume":"19","author":[{"given":"Munmun","family":"Mukherjee","sequence":"first","affiliation":[{"name":"Department of Pharmacology, NBMC&H, Darjeeling, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupam Nath","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, NBMC&H, Darjeeling, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumen","family":"Mukherjee","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, NBMC&H, Darjeeling, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaushik","family":"Ishore","sequence":"additional","affiliation":[{"name":"Department of Community Medicine, MJN Medical College, Cooch Behar, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,4,30]]},"reference":[{"key":"R2-20241021","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: Cancer J Clin"},{"key":"R3-20241021","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2165\/00019053-199915050-00003","article-title":"Counting the costs of drug-related adverse events","volume":"15","author":"White","year":"1999","journal-title":"Pharmacoeconomics"},{"key":"R6-20241021","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.21037\/atm.2018.10.38","article-title":"Concurrent chemoradiotherapy for stage III non-small cell lung cancer: Correct clinical management as the basis to move beyond","volume":"6","author":"Costa","year":"2018","journal-title":"Ann Transl Med"},{"key":"R7-20241021","doi-asserted-by":"crossref","first-page":"190","DOI":"10.21037\/tlcr.2016.04.08","article-title":"Pros: Concurrent chemo-radiotherapy remains the ideal treatment in fit patients with large volume unresectable stage III non-small cell lung cancer","volume":"5","author":"Rabatic","year":"2016","journal-title":"Transl Lung Cancer Res"},{"key":"R8-20241021","doi-asserted-by":"crossref","first-page":"32","DOI":"10.4103\/lungindia.lungindia_321_17","article-title":"Adverse effects observed in lung cancer patients undergoing first-line chemotherapy and effectiveness of supportive care drugs in a resource-limited setting","volume":"36","author":"Muthu","year":"2019","journal-title":"Lung India"},{"key":"R9-20241021","doi-asserted-by":"crossref","first-page":"687","DOI":"10.4103\/0250-474X.174990","article-title":"Prospective observational study of adverse drug reactions of anticancer drugs used in cancer treatment in a tertiary care hospital","volume":"77","author":"Medhi","year":"2015","journal-title":"Indian J Pharm Sci"},{"key":"R10-20241021","doi-asserted-by":"crossref","first-page":"593","DOI":"10.5530\/jyp.2017.9.113","article-title":"Chemotherapy induced adverse drug reactions in cancer patients in a tertiary care hospital in South India","volume":"9","author":"Behera","year":"2017","journal-title":"J Young Pharm"},{"key":"R11-20241021","doi-asserted-by":"crossref","first-page":"110","DOI":"10.4103\/jrptps.JRPTPS_68_20","article-title":"Incidence and cost of chemotherapy-induced adverse drug reactions among cancer patients in a charitable hospital","volume":"10","author":"Mateti","year":"2021","journal-title":"J Rep Pharm Sci"},{"key":"R12-20241021","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.4103\/jfmpc.jfmpc_352_20","article-title":"Frequency, nature, severity and preventability of adverse drug reactions arising from cancer chemotherapy in a teaching hospital","volume":"9","author":"Das","year":"2020","journal-title":"J Family Med Prim Care"},{"key":"R13-20241021","doi-asserted-by":"crossref","first-page":"273","DOI":"10.4103\/ijp.IJP_544_17","article-title":"A retrospective analysis of reporting of adverse drug reactions to oncology drugs: An experience from a national center of clinical excellence","volume":"50","author":"Misra","year":"2018","journal-title":"Indian J Pharmacol"},{"key":"R14-20241021","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1001\/jama.279.15.1200","article-title":"Incidence of adverse drug reactions in hospitalized patients","volume":"279","author":"Lazarou","year":"1998","journal-title":"JAMA"},{"key":"R18-20241021","first-page":"Spec No: 30","article-title":"Pharmacology of platinum analogs-taxanes interactions","volume":"87","author":"Boisdron-Celle","year":"2000","journal-title":"Bull Cancer"},{"issue":"Suppl 2","key":"R19-20241021","article-title":"A review of the pharmacokinetics and pharmacodynamics of combination carboplatin\/paclitaxel","volume":"24","author":"Calvert","year":"1997","journal-title":"Semin Oncol"},{"key":"R20-20241021","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2147\/IJCTM.S187569","article-title":"Chemotherapy-induced anemia: Etiology, pathophysiology, and implications for contemporary practice","volume":"6","author":"Bryer","year":"2018","journal-title":"Int J Clin Transfus Med"},{"key":"R21-20241021","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s12328-011-0257-2","article-title":"Severe cholestatic liver failure associated with gemcitabine adjuvant monotherapy for pancreatic cancer","volume":"4","author":"Okada","year":"2011","journal-title":"Clin J Gastroenterol"},{"key":"R22-20241021","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1007\/s00520-015-2809-3","article-title":"Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (actual data of vomiting incidence by chemotherapy evaluation) study","volume":"23","author":"Escobar","year":"2015","journal-title":"Support Care Cancer"},{"key":"R23-20241021","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1177\/1758834009355164","article-title":"Review: Chemotherapy-induced diarrhea: Pathophysiology, frequency and guideline-based management","volume":"2","author":"Stein","year":"2009","journal-title":"Ther Adv Med Oncol"},{"key":"R24-20241021","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3329\/dujps.v8i1.5330","article-title":"Pattern of adverse drug reactions due to cancer chemotherapy in tertiary care teaching hospital in Bangladesh","volume":"8","author":"Poddar","year":"1970","journal-title":"Dhaka Univ J Pharm Sci"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_522_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:38:41Z","timestamp":1787067521000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_522_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":18,"journal-issue":{"issue":"Suppl 2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_522_22","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"2022-03-03","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}